Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
ORGANIZATION
Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
The Japan Digital Therapeutics Consortium, which is made up of seven companies including drug makers developing therapeutic apps, is calling for the introduction of a fast-track approval system and new pricing rules for such products. Rie Fukaya, global clinical regulatory…
To read the full story
Related Article
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- Keidanren Calls for Clearer Classification Criteria for “Software as a Medical Device” to Promote Development
October 21, 2020
- Mitsubishi Tanabe to Develop Mobile App for Depression Treatment
September 3, 2020
- Astellas Links Up with US Health Tech Welldoc in Digital Therapeutics
November 22, 2019
- Shionogi Bags Japan/Taiwan Rights to Akili’s Digital Medicines for ADHD, Autism
March 8, 2019
ORGANIZATION
- Japan Generic Use Rate at 84.7% in July-September: JGA
December 27, 2024
- PhRMA/EFPIA Lash Out at Japan’s Plan for Mandatory Startup Fund
December 26, 2024
- PhRMA/EFPIA Slam Govt for Off-Year Revision as Broader Industry Deplores Decision
December 26, 2024
- Off-Year Revisions Need Careful Assessments and Discussions: Chuikyo JMA Rep
December 20, 2024
- JPMA to Continue Seeking Repeal of Off-Year Revisions: Exec
December 20, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…